Howell SB - Search Results

1

Preclinical development of tuspetinib for the treatment of acute myeloid leukemia.

Sonowal H, Rice WG, Bejar R, Byun JY, Jung SH, Sinha R, Howell SB. Sonowal H, et al. Among authors: howell sb. Cancer Res Commun. 2024 Dec 12. doi: 10.1158/2767-9764.CRC-24-0258. Online ahead of print. Cancer Res Commun. 2024. PMID: 39665627 Free article.

2

APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.

Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG. Local A, et al. Among authors: howell sb. Mol Cancer Ther. 2018 Jun;17(6):1177-1186. doi: 10.1158/1535-7163.MCT-17-1209. Epub 2018 Apr 6. Mol Cancer Ther. 2018. PMID: 29626127

3

Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.

Sonowal H, Zhang H, Rice W, Howell SB. Sonowal H, et al. Among authors: howell sb. Biochem Pharmacol. 2022 Jan;195:114861. doi: 10.1016/j.bcp.2021.114861. Epub 2021 Nov 26. Biochem Pharmacol. 2022. PMID: 34843717 Free article.

4

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.

Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE, Lo P, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Rice WG, et al. Among authors: howell sb. Mol Cancer Ther. 2022 Jul 5;21(7):1125-1135. doi: 10.1158/1535-7163.MCT-21-0832. Mol Cancer Ther. 2022. PMID: 35499387 Free PMC article.

5

Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.

Sonowal H, Rice WG, Howell SB. Sonowal H, et al. Among authors: howell sb. PLoS One. 2023 Mar 8;18(3):e0277003. doi: 10.1371/journal.pone.0277003. eCollection 2023. PLoS One. 2023. PMID: 36888611 Free PMC article.

6

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.

Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB. Tsai CY, et al. Among authors: howell sb. Mol Cancer Ther. 2018 Jun;17(6):1167-1176. doi: 10.1158/1535-7163.MCT-17-0834. Epub 2018 Apr 6. Mol Cancer Ther. 2018. PMID: 29626126 Free PMC article.

7

Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma.

Andrews PA, Jones JA, Varki NM, Howell SB. Andrews PA, et al. Among authors: howell sb. Cancer Commun. 1990;2(2):93-100. doi: 10.3727/095535490820874641. Cancer Commun. 1990. PMID: 2372473

8

Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.

Howell SB, Hom D, Sanga R, Vick JS, Abramson IS. Howell SB, et al. Cancer Res. 1989 Jun 15;49(12):3178-83. Cancer Res. 1989. PMID: 2720673

9

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.

Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Katano K, et al. Among authors: howell sb. Cancer Res. 2002 Nov 15;62(22):6559-65. Cancer Res. 2002. PMID: 12438251

10

Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.

McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. McClay EF, et al. Among authors: howell sb. Cancer Res. 1993 Apr 1;53(7):1571-6. Cancer Res. 1993. PMID: 8453625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters